JNJ Stock Analysis — Johnson & Johnson
Sector: Healthcare
AI Verdict
JNJ trades at 19.8x next year's earnings while analysts expect 50.2% EPS growth—cheap for the growth if its diversified moat and pipeline deliver, but the overbought RSI means a near-term pullback is likely.
Competitive Moat
Johnson & Johnson owns a portfolio of globally recognized consumer health brands, patented pharmaceuticals, and medical devices, giving it diversification and pricing power across healthcare segments. Its deep regulatory expertise and entrenched distribution networks make it hard for new entrants to compete at scale.
Summary
A 50.2% forward EPS growth forecast is driving attention as JNJ pivots from consumer health to higher-margin pharma and medtech.
Where It Stands
JNJ is up 63.79% over the past year, trades at 19.8x next year's earnings (vs. a 22x sector median), and its RSI of 70.5 signals overbought territory.
Key Metrics
- RSI: 70.5 — Overbought
- Trailing P/E: 29.7x
- Forward P/E: 19.8x
- PEG Ratio: 0.59
- Earnings Growth: +0.5%
- Market Cap: $618.6B
- 1-Year Return: 63.79%
Analyst Consensus
21 Buy · 10 Hold · 0 Sell (31 analysts) · Target $278.50
Bull Case
With analysts expecting 50.2% EPS growth and a forward P/E of 19.8x, you're paying less than the sector median for unusually high growth.
Bear Case
An RSI of 70.5 means the stock is overbought, so a pullback to a neutral RSI could erase a chunk of recent 63.79% gains.
Catalyst to Watch
Watch for regulatory approvals or setbacks in its pharma pipeline, as these will directly impact whether the 50.2% EPS growth materializes.